Allianz Asset Management GmbH Decreases Stake in Illumina, Inc. $ILMN

Allianz Asset Management GmbH lowered its position in Illumina, Inc. (NASDAQ:ILMN) by 29.6% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 10,220 shares of the life sciences company’s stock after selling 4,288 shares during the period. Allianz Asset Management GmbH’s holdings in Illumina were worth $975,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Rise Advisors LLC lifted its position in Illumina by 173.6% during the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after buying an additional 224 shares in the last quarter. Golden State Wealth Management LLC lifted its position in Illumina by 123.2% during the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock worth $42,000 after buying an additional 292 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its position in Illumina by 2,936.8% during the first quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock worth $46,000 after buying an additional 558 shares in the last quarter. Blue Trust Inc. lifted its position in Illumina by 63.1% during the second quarter. Blue Trust Inc. now owns 654 shares of the life sciences company’s stock worth $62,000 after buying an additional 253 shares in the last quarter. Finally, WPG Advisers LLC purchased a new position in Illumina during the first quarter worth approximately $58,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Royal Bank Of Canada set a $124.00 price objective on Illumina in a research report on Tuesday, September 2nd. Robert W. Baird set a $105.00 price objective on Illumina in a research report on Friday. Stephens set a $110.00 target price on Illumina and gave the company an “overweight” rating in a research report on Monday, August 4th. Barclays lifted their target price on Illumina from $90.00 to $95.00 and gave the company an “underweight” rating in a research report on Thursday, October 2nd. Finally, Daiwa America downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 12th. Five investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $115.25.

Illumina Price Performance

ILMN stock opened at $100.11 on Monday. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $15.39 billion, a PE ratio of 12.67, a P/E/G ratio of 2.47 and a beta of 1.40. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The business’s fifty day moving average price is $98.17 and its 200 day moving average price is $91.76.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the business earned $0.36 EPS. The company’s quarterly revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.